Multitude AG: Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution10. Mar 2026 / 07:46 CET/CEST, transmitted by GlobeNewswire.The issuer is solely responsible for the content of this announcement.Multitude AG: Multitude Capital Oyj explores the possibility to issue Subordinated Perpetual Floating Rate Callable Capital Notes and announces a tender offer, of its intention to together with its parent company Multitude AG early redeem Multitude AG’s outstanding capital notes with ISIN NO0011037327   Zug, 10 March 2026 –  Wholly owned subsitiady of Multitude AG Multitude Capital Oyj (the “Company“), hereby announces that it has mandated Pareto Securities AB as global coordinator and Pareto Securities AB and Seaport Global Securities LLC...

Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and BahrainAllschwil, Switzerland – March 10, 2026Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented:“We are delighted to partner with Pharmalink, a leading healthcare provider that shares our bold vision for QUVIVIQ‘s growth across the UAE and other Gulf states. I am confident that this partnership will ensure that many patients gain access to our innovative...

PRESS RELEASEMarch 10, 2026RENAULT GROUP LAUNCHES futuREady OPENING A NEW STRATEGIC ERARenault Group is moving into high gear, turning the success story of the Renaulution plan into a success system that is both sustainable and global. With the new strategic plan futuREady, the Group is seeking to maintain its growth dynamic and become the reference European carmaker. futuREady revolves around the product and the customer experience, technological innovation and operational excellence. At the same time, it is based on a strong commitment to employees, suppliers, dealer networks and partners. The product remains front and centre of this strategy. Renault Group will launch 36 new models between now and 2030, accelerating electrification and also its international line-up. Over the medium term, Renault Group aims to generate consistently...

(Bergen, 10 March 2026). Mowi is pleased to announce that we have entered into a Transaction Agreement to purchase all of Torghatten Aqua AS’s salmon farming seawater business. Torghatten Aqua is a salmon farming conglomerate in production area 8 in Northern Norway that is engaged in several activities including renting out salmon licenses and seawater sites (joint operation agreement with a third party) to school activities, land-based salmon farming and consulting. Upon Mowi’s acquisition of Nova Sea last year, we became the owner of a 33.34% stake in Torghatten Aqua. Mowi has now entered into an agreement to carve-out and purchase 3.37 licenses in total (2,628 tonnes maximum allowed biomass); 1.37 commercial license, 1 exhibition license and 1 education license. We expect to harvest around 4,500 GWT annually from this license portfolio. “Torghatten’s...

Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years with Santhera and will remain available to support an orderly transition over the coming months. Proven commercial leadership to drive Santhera’s next phase of growth Marc Clausse brings over 25 years of international experience in the life sciences industry, with deep expertise across specialty, oncology and rare diseases. He has a strong track record of building high-performing teams, leading complex international organizations, and delivering sustained commercial growth in both emerging biotech and established specialty pharmaceutical companies. His experience spans the full commercial value chain,...

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial HighlightsTotal Medical Device sales rose by 72%, or USD 60.9 million, to USD 146.1 million (2024: USD 85.2 million) Direct MagnetOs™ sales increased by 71% to USD 143.9 million (2024: USD 84.3 million) Total Group EBITDA reached USD 12.4 million (2024: USD 2.4 million) Total Group adjusted EBITDA* arrived at USD 19.6 million, resulting in a margin of 13.4% (2024: USD 10.1 million at 11.9%) For the first time in the company’s history, the Group delivered a net profit of USD 2.6 million (2024: net loss of USD (4.8) million) Cash and cash equivalents stood at USD 19.8 million, reflecting a strong operational cash flow generation allowing for continued substantial...

VANCOUVER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce that it will be reporting its financial results for the year ended December 31, 2025 (“Q4 2025”) after market close on Monday, March 23, 2026. The Company will be hosting a conference call to discuss Q4 2025 results on Tuesday, March 24, 2026. Conference call details are as follows:Time: 7:00 AM PT / 10:00 AM ETConference ID: 68562Local dial-in:         (+1) 289 514 5100Toll Free N. America: (+1) 800 717 1738Webcast: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=2A9CD702-2774-4357-AB08-7BF1F20DC002    ABOUT...

NINGDE, China, March 09, 2026 (GLOBE NEWSWIRE) — Oriental Rise Holdings Limited (NASDAQ: ORIS) (“Oriental Rise” or the “Company”), an integrated tea supplier in mainland China, today announced that its operating subsidiary Fujian Mindong Hong Tea Industry Technology Co., Ltd. (“Mindong Hong”) has entered into a strategic cooperation agreement with Shandong Yiyang Zhongji New Energy Co., Ltd. (“Zhongji New Energy”), a renewable energy developer, to explore the deployment of solar photovoltaic power generation systems within the Company’s tea plantation bases. The collaboration is designed to evaluate the integration of agriculture and renewable energy infrastructure, a model often referred to as “agro-photovoltaic” development, which enables solar power generation while maintaining agricultural cultivation activities. Under the...

$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold 12,094,631 shares of common stock (or pre-funded warrants in lieu thereof) Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase...